Latest Security News

Cleo Diagnostics (ASX:COV) has hit a major milestone by completing sample collection for its pivotal U.S. ovarian cancer trial, while progressing manufacturing and analytical validation steps toward FDA 510(k) submission.

Dundas Minerals has secured $2.5 million to fund extensive drilling across its Western Australian gold portfolio, exercised its option to acquire the Rockland mining lease, and expanded the Romano project with a new exploration licence application near Gruyere.

Neometals Ltd has launched a 1-for-6 entitlement offer at A$0.04 per share alongside a two-tranche placement, targeting a combined A$13 million to advance gold and critical minerals projects.

West Wits Mining has poured its first gold at Qala Shallows, marking its transition to production, while securing substantial funding and advancing plans to scale output.

Altitude Minerals reported encouraging aircore drill results at its Byrock Project in NSW, confirming copper-gold porphyry signatures and advancing a joint venture with Nimrod Resources. In Nevada, the company validated high-grade silver-gold targets at Firenze, readying a 2,600m RC drill program.

CuFe Ltd has boosted confidence in its Orlando Copper-Gold Deposit by upgrading 87% of the resource to Indicated, paving the way for development studies and a substantial drilling campaign.

Victory Metals has reported record rare earth oxide grades and exceptional metallurgical results at its North Stanmore project, alongside strategic partnerships and heritage clearances that unlock exploration potential.

Silver Mines Limited is progressing its Bowdens Silver Project development application with updated ecological surveys, while exploration intensifies at the Rockwell Prospect and Californian assets, supported by a solid cash position.

Prodigy Gold has boosted the indicated resource at its Hyperion Gold Deposit by 70%, lifting total resources to 454,000 ounces and progressing key mining approvals and joint ventures.

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Zeotech pushed forward its AusPozz™ metakaolin commercialisation with extended and new MOUs, progressed key Toondoon project approvals amid rising contractor costs, and launched live methane control trials.

Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.